Divi’s Labs Q2 Net Profit Rises 35%; Shares Snap Six-Session Winning Streak | Stock Market Today

Market Performance

The stock market today saw Divi’s Labs shares take a pause after a strong run over the past week. At 1:45 pm on November 7, Divi’s Labs share price slipped 3% to ₹6,661, ending a six-session winning streak during which the stock had climbed 7%.

The pullback came despite strong quarterly results, reflecting profit booking after consecutive gains. Investors’ attention remains focused on the company’s robust financial performance and its growing presence in global pharmaceutical markets.

Q2 Financial Highlights

Divi’s Labs reported a strong second quarter for FY26, with key financials showing healthy growth:

• Consolidated Net Profit: ₹689 crore, up 35% YoY from ₹510 crore in Q2 FY25.
• Revenue from Operations: ₹2,115 crore, a 16% YoY rise.
• Total Expenses: ₹1,886 crore, up 13% YoY and 9% sequentially.
  • Raw Material Costs: ₹907 crore, down 5% YoY, accounting for 48% of total expenses.
  • Employee Benefits Expense: ₹344 crore, up 16% YoY.
  • Other Expenses: ₹370 crore, up 15% YoY.
  • Depreciation & Amortisation: ₹113 crore, up 15% YoY.

For the first half of FY26, the company’s numbers were equally impressive:

• Net Profit: ₹1,253 crore, up 32% YoY.
• Revenue from Operations: ₹5,017 crore, a 15% YoY rise.

The results highlight Divi’s Labs’ efficient operations and its knack for controlling costs even as revenue grows.

Company Overview

Divi’s Labs is one of India’s leading manufacturers of active pharmaceutical ingredients (APIs). The company exports to more than 100 countries, with the United States and Europe being its primary markets.

APIs are critical components in drugs that deliver therapeutic effects. Divi’s Labs’ extensive global presence positions it to benefit from growing demand, particularly from manufacturers of diabetes and weight-loss medications, where global consumption is on the rise.

Summary

Divi’s Labs delivered solid Q2 results, with a 35% jump in net profit and 16% growth in revenue. Despite the slight decline in Divi’s Labs' share price today, the company’s underlying performance remains strong, reflecting resilience in operations and continued global market demand.

The stock’s performance over 2025 also highlights its stability: so far, Divi’s Labs shares have risen 11%, outperforming the pharma index, which declined 5% during the same period.